lilrb4 star-t
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 24, 2022 (NCT05518357)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05739409 | N/A | Feb 28, 2023 | China Academy of Chinese Medical Sciences |
| NCT05548088 | Phase 1 | Nov 30, 2022 | Beijing Qingyi Taike Pharmaceutical Technology Co., Ltd, Peking University |
| NCT05518357 | Phase 1 | Jun 24, 2022 | Ludaopei Hospital |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing Qingyi Taike Pharmaceutical Technology Co., Ltd | For profit | 1 | 0 | 1 | 2022 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Ludaopei Hospital | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1